LYN-005

LYN-005 is an ultra-long acting, once-weekly oral formulation of risperidone developed by Lyndra Therapeutics. It utilizes the proprietary LYNX drug delivery platform to provide sustained and consistent release of risperidone over a week, aiming to improve medication adherence and reduce pill burden for individuals with schizophrenia and schizoaffective disorder. The mechanism of action is through antagonism of dopamine D2 receptors and serotonin 5-HT2A receptors in the brain, which helps attenuate psychosis and stabilize mood. Clinical studies have demonstrated that weekly dosing with LYN-005 achieves pharmacokinetic bio-comparability to daily immediate-release risperidone (Risperdal), maintaining efficacy as measured by Positive And Negative Symptom Scale (PANSS) scores while offering a favorable safety profile[1][4][5][6]. The innovation addresses challenges such as missed doses due to daily regimens and aims to mitigate side effects associated with peak drug concentrations[1].

Brand names

LYN-005LYN005LYN 005

Other names

oral weekly risperidonerisperidone extended release (LYN-005)